These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21426147)

  • 21. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug discovery: the leading edge.
    Chapman T
    Nature; 2004 Jul; 430(6995):109-15. PubMed ID: 15229608
    [No Abstract]   [Full Text] [Related]  

  • 23. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.
    Baell JB; Holloway GA
    J Med Chem; 2010 Apr; 53(7):2719-40. PubMed ID: 20131845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell culture-based models for intestinal permeability: a critique.
    Balimane PV; Chong S
    Drug Discov Today; 2005 Mar; 10(5):335-43. PubMed ID: 15749282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [NMR-based screening of protein inhibitors in drug discovery].
    Hu HY
    Yao Xue Xue Bao; 2002 Feb; 37(2):158-60. PubMed ID: 12579966
    [No Abstract]   [Full Text] [Related]  

  • 26. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automatic mass spectrometry method development for drug discovery: application in metabolic stability assays.
    Chovan LE; Black-Schaefer C; Dandliker PJ; Lau YY
    Rapid Commun Mass Spectrom; 2004; 18(24):3105-12. PubMed ID: 15565734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystallography, NMR and virtual screening: integrated tools for drug discovery.
    Muchmore SW; Hajduk PJ
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):544-9. PubMed ID: 12951817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance.
    Huth JR; Song D; Mendoza RR; Black-Schaefer CL; Mack JC; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Hajduk PJ
    Chem Res Toxicol; 2007 Dec; 20(12):1752-9. PubMed ID: 18001056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput screening: update on practices and success.
    Fox S; Farr-Jones S; Sopchak L; Boggs A; Nicely HW; Khoury R; Biros M
    J Biomol Screen; 2006 Oct; 11(7):864-9. PubMed ID: 16973922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection criteria for drug-like compounds.
    Muegge I
    Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based screening and design in drug discovery.
    van Dongen M; Weigelt J; Uppenberg J; Schultz J; Wikström M
    Drug Discov Today; 2002 Apr; 7(8):471-8. PubMed ID: 11965396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SAR by ILOEs: an NMR-based approach to reverse chemical genetics.
    Becattini B; Pellecchia M
    Chemistry; 2006 Mar; 12(10):2658-62. PubMed ID: 16121405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolution of microarrayed compound screening.
    Hoever M; Zbinden P
    Drug Discov Today; 2004 Apr; 9(8):358-65. PubMed ID: 15081963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabonomics in pharmaceutical discovery and development.
    Robertson DG; Reily MD; Baker JD
    J Proteome Res; 2007 Feb; 6(2):526-39. PubMed ID: 17269709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis.
    Mortishire-Smith RJ; O'Connor D; Castro-Perez JM; Kirby J
    Rapid Commun Mass Spectrom; 2005; 19(18):2659-70. PubMed ID: 16124034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear magnetic resonance in target profiling and compound file enhancement.
    Sun C; Hajduk PJ
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):463-70. PubMed ID: 16889229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fragment-based screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12.
    Boettcher A; Ruedisser S; Erbel P; Vinzenz D; Schiering N; Hassiepen U; Rigollier P; Mayr LM; Woelcke J
    J Biomol Screen; 2010 Oct; 15(9):1029-41. PubMed ID: 20855559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.